Day 2 Program

General Session 1

Day 2: December 10, 2025

9:30 AM–12:00 PM CST

Hall 1

Session Details

The text of the abstracts will be posted on Monday, November 24.

Moderator

Stefan Glück

Moderator

Rita Nanda

GS1-01

Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer

Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN

GS1-02

Efficacy and safety of neoadjuvant trastuzumab deruxtecan versus standard of care chemotherapy plus trastuzumab plus pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV

Nadia Harbeck, LMU University Hospital, Munich, Germany

GS1-03

Discussant for GS1-01 and GS1-02: Evolving landscape of her2+ breast cancer

Ciara C O'Sullivan, Mayo Clinic, Rochester, MN

GS1-04

Adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive/HER2-positive early breast cancer: An exploratory analysis from the ALTTO (BIG 2-06) trial

Matteo Lambertini, University of Genova – IRCCS Ospedale Policlinico San Martino, Genoa, Italy

GS1-05

Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN-1181/CompassHER2 pCR trial

Sunil S Badve, Emory School of Medicine, Atlanta, GA

GS1-06

Prognostic and predictive associations of manual, digital and AI-derived tumor infiltrating lymphocytes-scoring: A retrospective analysis from the Phase III APHINITY trial

Roberto Salgado, Peter MacCallum Cancer Centre, Melbourne, Australia

GS1-07

Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC): Translational analysis of PHERGain neoadjuvant tailored treatment study

Antonio Llombart-Cussac, Hospital Arnau de Vilanova; Translational Oncology Group, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU; Medica Scientia Innovation Research (MedSIR), Valencia, Spain

GS1-08

Discussant for GS1-05, GS1-06, GS1-07

Heather A Parsons, Fred Hutchinson Cancer Center, Seattle, WA

GS1-09

Multimodal artificial intelligence (AI) models integrating image, clinical, and molecular data for predicting early and late breast cancer recurrence in TAILORx

Joseph A Sparano, Icahn School of Medicine at Mount Sinai, New York, NY

GS1-10

Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2− (IHC 0, 1+, 2+/ISH−) metastatic breast cancer: Primary results from ASCENT-07

Komal L. Jhaveri, Memorial Sloan Kettering Cancer Center (MSKCC); Weill Cornell Medical College, New York, NY